The 3 Most Promising Big Pharma Dividends for the Next 5 Years

Few industries provide the same kind of dividend power as big pharma. Between top-selling drugs, cash-cow medications, and up-and-coming blockbusters, pharmaceutical companies like Pfizer and Johnson & Johnson boast the financial fortitude and portfolio firepower to provide for dividend investors for years to come.

Yet in an industry as competitive as this, which are the best stocks for dividend investors to target? Johnson & Johnson's breadth has provided a strong, stable base for dividend investors for the long term, but with the company's medical device business slowing, is this stock slumping out of the top segment of health care stocks?

Not to worry, Johnson & Johnson investors. In the video below, Fool contributor Dan Carroll shows you three big pharma stocks -- including J&J -- that have the potential to transform portfolios in the long run and deliver the types of dividends that will reward investors handsomely for years to come.

The best way to win with your dividend stock picks
Pfizer and Johnson & Johnson are two of health care's top names and members of the Dow Jones, but are they the best blue-chip dividend stocks for your money? If you're looking for some long-term investing ideas, you're invited to check out The Motley Fool's brand-new special report, "The 3 Dow Stocks Dividend Investors Need." It's absolutely free, so simply click here now and get your copy today.

The article The 3 Most Promising Big Pharma Dividends for the Next 5 Years originally appeared on

Fool contributor Dan Carroll has no position in any stocks mentioned. The Motley Fool recommends Johnson & Johnson. The Motley Fool owns shares of Johnson & Johnson. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.

Read Full Story